Construction and validation of a prognostic model for stage IIIC endometrial cancer patients after surgery |
| |
| Institution: | 1. Department of Radiation Oncology, Chengdu Women''s and Children''s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 611731, China;2. Department of Medical Oncology, Sichuan Cancer Hospital&Institute, Chengdu, 610042, China;3. Department of Radiology, Chengdu Women''s and Children''s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 611731, China;4. Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400000, China;1. Department of General Surgery, Guy''s and St Thomas'' NHS Trust, London, UK;2. Department of General Surgery, Queen Alexandra Hospital, Portsmouth University Hospital NHS Trust, Portsmouth, UK;3. Department of General Surgery, Oxford University Hospital NHS Foundation Trust, Oxford, UK;4. School of Cancer Sciences, Faculty of Medicine, University of Southampton, UK;5. School of Cancer and Pharmaceutical Sciences, King''s College London, London, UK;6. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden;1. Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands;2. Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands;3. Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands;4. Department of Surgical Oncology, University Medical Centre Utrecht, Utrecht, the Netherlands;5. Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands;6. Department of Surgical Oncology, Leiden University Medical Centre, Leiden, the Netherlands;7. Department of Surgical Oncology, University Medical Centre Groningen, Groningen, the Netherlands;8. Department of Surgical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands;9. Department of Surgical Oncology, Maastricht University Medical Centre+, Maastricht, the Netherlands;1. Washington Cancer Institute, Program in Peritoneal Surface Malignancy Washington, DC, USA;2. Westat, Rockville, MD, USA;1. UGC Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain;2. Department of Medical Oncology, IMIBIC, Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III, Hospital Universitario Reina Sofía, Córdoba, Spain;3. Department of Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain;4. Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain;5. Department of Medical Oncology, University Hospital Marqués de Valdecilla, IDIVAL, Santander, Spain;6. Department of Medical Oncology, Hospital General Universitario Valencia, Universidad de Valencia, CIBERONC, Valencia, Spain;7. Department of Medical Oncology, Instituto Oncológico Dr. Rosell, Barcelona, Spain;8. Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC), University Complutense, CIBERONC, Madrid, Spain;9. Department of Medical Oncology, Hospital Virgen del Rocío, IBIS, Sevilla, Spain;10. Department of Medical Oncology, IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal, Madrid, Spain;11. Department of Medical Oncology, Hospital Virgen de las Nieves, Granada, Spain;12. Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain;13. Department of Medical Oncology, Hospital de Lleida Arnau de Vilanova, Lérida, Spain;14. Department of Medical Oncology, Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria de Aragón (IISA), Zaragoza, Spain;15. Department of Medical Oncology, Hospital del Mar Medical Research Institute, CIBERONC, Barcelona, Spain;p. Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain;1. Department of Surgery, Franciscus Gasthuis & Vlietland, Rotterdam, Schiedam, the Netherlands;2. Department of Surgery, division of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands;3. Department of Intensive Care Medicine, Elisabeth-Tweesteden Hospital, Tilburg, the Netherlands;4. Department of Research & Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands;5. Department of Surgery, IJsselland Hospital, Capelle aan den IJssel, the Netherlands;6. Department of Surgery, division of Surgical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands;1. Department of Nuclear Medicine, Tata Memorial Hospital and Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, 400012, India;2. Division of Colorectal Surgery, Department of Surgical Oncology, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, Maharashtra, 400012, India;3. Department of Medical Gastroenterology, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, Maharashtra, 400012, India;4. Department of Radiation Oncology, Tata Memorial, Hospital and Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, 400012, India |
| |
| Abstract: | BackgroundTo explore the most predictive lymph node (LN) scheme for stage IIIC endometrial cancer (EC) patients after hysterectomy and develop a scheme-based nomogram.MethodsData from 2626 stage IIIC EC patients, diagnosed between 2010 and 2014, were extracted from the Surveillance, Epidemiology, and End Results (SEER) registry. The predictive ability of four LN schemes was assessed using C-index and Akaike information criterion (AIC). A nomogram based on the most predictive LN scheme was constructed and validated. The comparison of the predictive ability between nomogram and FIGO stage was conducted using the area under the receiver operating characteristic curve (AUC) and decision curve analysis (DCA).ResultsFIGO stage (stage IIIC1/stage IIIC2) was not an independent risk factor for OS in stage IIIC EC patients (P = 0.672) and log odds of positive lymph nodes (LODDS) had the best predictive ability (C-index: 0.742; AIC: 8228.95). A nomogram based on LODDS was constructed and validated, which had a decent C-index of 0.742 (0.723–0.762). The nomogram showed a better predictive ability than that of the FIGO staging system.ConclusionFIGO IIIC1/FIGO IIIC2 could not differentiate the prognosis for stage IIIC EC patients. We developed and validated a nomogram based on LODDS to predict OS for post-operative patients with stage IIIC EC. |
| |
| Keywords: | Endometrial cancer Stage IIIC Nomogram SEER Prognosis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
